Radiofrequency Ablation in Resectable Colorectal Lung Metastasis: A Phase-II Clinical Trial
This will be a phase-II clinical trial.
Lung metastasectomy is the only therapeutic option to provide a long-survival in patients
with colorectal lung metastases. Recent studies have shown that radiofrequency (RF) ablation
is a safe and useful therapeutic option for the treatment of unresectable lung metastases.
In this clinical trial, clinical utility of lung RF ablation will be evaluated.
Patients with resectable lung metastases will receive lung RF ablation.
All subjects will be followed for overall survival, safety, change in respiratory function,
cancer-specific survival, and local tumor progression.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary Outcome Measures:3-year survival
3 years
Yes
Haruyuki Takaki, MD
Study Director
Department of Radiology, Mie University School of Medicine
Japan: Institutional Review Board
2008-993 Mie-U-IRB
NCT00776399
October 2008
November 2014
Name | Location |
---|